



Paclitaxel, albumin bound

Agent	Brand Name(s)	Disease	Pharmacologic Class	Histology	FDA Disease Indication	Route(s)	ICD-9 Code	NCCN Recommended Use	NCCN Category
Paclitaxel, albumin bound NCCN Chemotherapy Order Templates (Includes Evidence-based References)	Abraxane®	Breast Cancer - Invasive	Microtubule inhibitor		Albumin-bound paclitaxel is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. Consult the full FDA label with particular attention to boxed warning(s).	IV	174.0-174.6, 174.8, 174.9, 175.0, 175.9	Preferred single agent for patients with recurrent or metastatic disease: <ul style="list-style-type: none"> that is hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive or HER2-negative, with visceral crisis that is hormone receptor-negative, or hormone receptor-positive and endocrine therapy refractory 	2A
Paclitaxel, albumin bound	Abraxane®	Non-small cell lung cancer (NSCLC)	Microtubule inhibitor	Adenocarcinoma (with mixed subtypes); Squamous cell carcinoma; Large cell carcinoma	Albumin-bound paclitaxel is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. Consult the full FDA label with particular attention to boxed warning(s).	IV	162.0, 162.2-162.5, 162.8, 162.9	May be substituted for either paclitaxel or docetaxel in patients who have experienced hypersensitivity reactions after receiving paclitaxel or docetaxel despite premedication, or for patients in whom standard hypersensitivity premedications are contraindicated. Consider bisphosphonate** therapy for symptomatic bone metastases This regimen was added based on recent NCCN NSCLC panel deliberations	2A